Comparative Pharmacology

Head-to-head clinical analysis: MAGNESIUM SULFATE IN DEXTROSE 5 IN PLASTIC CONTAINER versus NIPRIDE RTU IN SODIUM CHLORIDE 0 9.

Peer-Reviewed Evidence

Differential Analysis

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER vs NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.

MAGNESIUM SULFATE IN DEXTROSE 5% IN PLASTIC CONTAINER

Electrolyte

Category C

NIPRIDE RTU IN SODIUM CHLORIDE 0.9%

Electrolyte

Category A/B

Head-to-Head

Clinical Matrix

Mechanism of Action

Magnesium sulfate provides magnesium ions, which are essential for various physiological processes. It acts as a cofactor for enzymatic reactions, stabilizes excitable membranes, and antagonizes calcium entry at the neuromuscular junction, leading to reduced acetylcholine release and muscle relaxation. In the CNS, it may act as a noncompetitive antagonist of NMDA receptors, exerting anticonvulsant effects.

Sodium nitroprusside is a potent vasodilator that acts by releasing nitric oxide (NO), which activates guanylyl cyclase in vascular smooth muscle cells, increasing cGMP levels and leading to relaxation of both arterial and venous smooth muscle, thereby reducing peripheral resistance and cardiac preload.

Clinical Dosing

1 to 4 g intravenously as a 5% to 20% solution, rate not exceeding 150 mg/min; dosing frequency depends on indication (e.g., preeclampsia/eclampsia: 4-5 g IV loading then 1-2 g/hr infusion; hypomagnesemia: 1-2 g IV over 1-2 hours, may repeat based on serum magnesium levels).

Initial 0.3-0.5 mcg/kg/min IV continuous infusion, titrate by 0.5 mcg/kg/min every 3-5 minutes to desired effect; usual range 3-6 mcg/kg/min; maximum 10 mcg/kg/min.

Direct Interaction

None Documented